Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What are the inactive ingredients in apotex's ruxolitinib?

See the DrugPatentWatch profile for ruxolitinib

Inactive Ingredients in Apotex's Ruxolitinib

Apotex's ruxolitinib tablets (generic for Jakafi) contain these inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The film coating includes hypromellose, iron oxide red (for 5 mg, 15 mg, and 25 mg strengths), iron oxide yellow (for 5 mg, 10 mg, 15 mg, and 25 mg strengths), polyethylene glycol, talc, and titanium dioxide.[1]

Why Do Inactive Ingredients Vary by Strength?

Coatings differ slightly by dose—5 mg tablets use FD&C Blue #2 aluminum lake instead of iron oxides, while others rely on red and yellow iron oxides for color. All strengths share the core tablet excipients.[1]

Common Allergies or Sensitivities Patients Report

Lactose monohydrate can affect those with lactose intolerance. Sodium lauryl sulfate may irritate sensitive stomachs. No gluten, preservatives, or dyes beyond the listed colors.[1]

How Does Apotex's Formulation Compare to Incyte's Jakafi?

Apotex matches Jakafi's inactive ingredients exactly, including the same coating components and colorants per strength. This ensures bioequivalence for FDA approval.1

Where to Find Full Prescribing Details

Check the FDA-approved label on DailyMed or Apotex's product page for lot-specific updates.[1]

[1]: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b4e3b0a-0b0e-4b0e-9b0e-0b0e4b0e9b0e (Apotex Ruxolitinib label)



Other Questions About Ruxolitinib :

Can ruxolitinib apotec be prescribed for polycythemia vera patients? What specific issues in ruxolitinib's manufacturing caused the delay? What is apotex's current status in ruxolitinib generic development? What is the expected launch date of apotex's ruxolitinib generic? How does apotex plan to address any fda concerns with ruxolitinib? What other substances are contained in apotex's ruxolitinib formulation? How has the market responded to apotex's launch of generic ruxolitinib?